In addition, there was no observed difference in %CXCR4+ between IPF patients on anti-fibrotic therapy (pirfenidone or nintedanib n = 10) or those who were not (n = 6). The gene discussed is CXCR4; the disease is idiopathic pulmonary fibrosis.